FOSUN TIMES 2013.4.30 … · 2013-05-09 · Senior Vice President of Fosun Pharma. Wanbang Pharma...

Preview:

Citation preview

FOSUN TIMES 2013.4.30

News

04

By�Yi�Jinyuan

■ FOSUN�TIMES�Subsequent�to�

its� listing� in� Hong� Kong,� Fosun�

Pharma� strategically� became�

more� focused�on�development� in�

pharmaceutical� manufacturing�

with� a� strategic� development�

model�of�“internal�growth,�exter-

nal� expansion� and� integrated� de-

velopment”.

Recently,�Fosun�Pharma�ac-

celerated� integration� of� strategic�

cardiovascular� product� supply�

chains.�Wanbang�Pharma,�one�of�

its�subsidiaries,�acquired�51%�eq-

uity� of� Zaozhuang� Sainuokang�

and� actively� engaged� in� interna-

tional� development� through� co-

operation�with� the�German� com-

pany�Biotest�and�the�US�company�

Saladax,� by� which� expanded� a-

gain� cooperation� models� with�

outstanding� overseas� pharmaceu-

tical� firms� and� comprehensively�

enhanced� competitiveness� in� the�

industry.

As�a�major�subsidiary�of�Fo-

sun� Pharma,� Wanbang� Pharma�

adhered�to�a�developmental�strat-

egy�of�“dual�directions�from�one�

centre” in� positioning� itself,�

meaning� centering� around� dia-

betes�medicines�while� expanding�

into� cardiovascular� and� anti-can-

cer�medicines.�Wanbang� Pharma�

is� the� largest� sodium� heparin� in-

jection� manufacturer� in� China�

and� a� leading� low� molecular�

weight� heparin� injection� manu-

facturer�in�the�country.�Heparin�is�

a� substance� extracted� from�

porcine� small� intestinal� mucus�

possessing� anticoagulant� effect�

and� is�widely� used� in� preventing�

and�treating�various�diseases,�It�is�

a� bio-medicine� with� the� largest�

sales�across�the�world�and�an�an-

ticoagulant�the�most�used.�In�Chi-

na,�a�country�accounting�for�most�

of� the� manufacture� and� exporta-

tion� of� its� raw�material,� it� occu-

pies� an� important� position� in�

medicine�export.

Sainuokang� Biochemical,� a�

company� specialized� in� produc-

tion�of�heparin�API,�has�a�leading�

position� in� China� with� its� new�

method,�technology�and�cost�con-

trol.�“Through� strategic� coopera-

tion� with� Ruicheng,� Wanbang�

Pharma� obtained� control� over�

Sainuokang�Biochemical,�thereby�

ensuring�stable�supply�of� sodium�

heparin� API� and� lowered� pur-

chase� cost� of� API.” Li� Xianlin,�

Senior� Vice� President� of� Fosun�

Pharma.

Wanbang� Pharma� also� en-

tered� into� an� agreement�with� the�

German� company� Biotest� in�

Shanghai� recently.� A� product� of�

Biotest,� is�exclusively�distributed�

by�Wanbang�Pharma�in�the�Main-

land� China� region.� Sales� of� hu-

man� serum� albumin� of� Chinese�

hospital�market� amounted� to� ap-

proximately� RMB3.5� billion� in�

2011.

Human�serum�albumin�is�an�

albumin�medicine�extracted�from�

blood� of� healthy� human,� mainly�

used�in�treatment�of�bleeding�and�

wound,� shock� caused� by� burns,�

high� intracranial� pressure� caused�

by�cerebral�edema�or�injury,�ede-

ma�or� ascites� caused� by� cirrhosis�

and�kidney�disease,�and�is�widely�

used�in�clinical�emergency.�In�re-

cent�years,�demand�of�it�increased�

in� the� market� of� China,� where�

there� were� shortages� of� related�

products�in�times.�Biotest,�a�glob-

ally� leading� company� of� blood�

and�bio-product� research�and�de-

velopment� and�manufacture,�was�

founded� in� 1946,� has� been� listed�

on� Frankfurt� Stock� Exchange�

since� 1987� and� was� included� in�

Deutsche� B觟rse� SDAX� index� in�

2007.� The� company� possesses�

outstanding� techniques� in� maxi-

mizing� separation� and� purifica-

tion� of� high-value� medicinal� in-

gredients,� where� the� techniques�

are�those�of�high�standards�in�col-

lection,� testing� and� manufactur-

ing�of�plasma�to�ensure�stable�and�

reliable�quality.�This�cooperation�

will�contribute�to�alleviating�tight�

supply� of� human� serum� albumin�

in� the�market� of� China� and� pro-

duce�a�great�social�effect.

In� addition,� Fosun� Pharma�

announced� its� entering� into� a� se-

ries� of� cooperative� agreements�

with� the� US� company� Saladax�

Biomedical,� Inc.� to� subscribe� for�

batch�D�of�additional�preferential�

shares�of�Saladax�at� a� considera-

tion� of� approximately� USD22.5�

million.�Upon�completion�of�such�

subscription,� Fosun� Pharma� will�

be� the� sole� majority� shareholder�

thereof.� Also,� Shanghai� Fosun�

Long�March�Medical�Science�Co.

,�Ltd,�a�subsidiary�of�Fosun�Phar-

ma,�entered�into�a�strategic�coop-

erative� agreement� with� Saladax,�

thereby�obtained�exclusive�distri-

bution� right� and� product� manu-

facture�right�within�China.

Saladax� possesses� advanced�

testing� technology� and�

chemotherapy�medicine�monitor-

ing�product�portfolio.�Such�coop-

eration� will� effectively� enhance�

innovative� capability� of� Fosun�

Pharma�in�medical�diagnosis�and�

enable� development� of� a� bio-test�

platform� in� China,� and� even� the�

international� market,� capable� of�

testing� concentration� and� other�

parameters� of� chemotherapy�

medicines�so�as�to�better�analysis�

effect�of�such�medicines� in� treat-

ments.� It� is� expected� that� such�

product�line�will�obtain�consider-

able�sales�scale�in�China.■

PFL Sales Office in Jiujiang Road Opened for Business

By�Flora�Shao

■ FOSUN� TIMES� [April� 16,�

2013�Shanghai]�Pramerica�Fosun�

Life� Insurance� (PFL)� staged� a�

grand� opening� ceremony� for� the�

Jiujiang�Road�Sales�Office� in� the�

Financial� Plaza,� Huangpu� Dis-

trict.� Shareholder/Prudential� rep-

resentatives� Bob� Fallon,� Senior�

Vice�President,�Bartholomew�Ng,�

Managing�Director� of�China� and�

Gaurang� Pandya,� Vice� President�

of� International� Department�

joined� the� opening� ceremony� to-

gether�with�PFL�General�Manag-

er�Wilson�Yeung�and�other�senior�

managers.��

During� the� ceremony,�

Steven�Zhou,�Tied�Agency�Head�

of�PFL�delivered� the�opening� re-

marks�by� thanking�all� colleagues�

and�partners�for�their�contribution�

to� the� channel;� he� also� encour-

aged� all� to� join� hand� together� to�

achieve�new�high.

Amid�drum�beats,�two�giant�

lions� mounted� on� the� stage� and�

started� to� dance,� culminating� at�

the�eye-dotting�ceremony,�it�sug-

gest�PFL�as�a�waking�lion�full�of�

power,�bound�to�grow�stronger.��

Three� shareholder� represen-

tatives,� Wilson� Yeung,� Steven�

Zhou� of� Tied� Agency� and�

Haidong� Shen� of� Bancassurance�

jointly� unveiled� the� sales� office.�

While� the� red� ribbon�was�drawn�

and� the� salute� was� fired,� a� roll�

printed� with� "Ambitious� Devel-

opment� and� Booming� Business"�

came�out� from� the�mouth�of� the�

lions,�it�represents�the�best�wish-

es�of� all� guests� for� a� rosy� future�

of�PFL�from�all�guest.�

Wilson,�Bart�and�sharehold-

er�representatives�made�speeches�

in�order;� they�saw� the�day�as�an�

important� moment� for� PFL� as�

this�is�the�first�sales�office�of�the�

company.�With� the�expansion�of�

the�company�and� the� staff,�more�

sales� offices� will� be� opened� to�

meet� customers'� needs.� Both�

shareholders� are� ready� to� pro-

vide�more� support�and� resources�

to� the� company,� they� highly�

praised� and� recognized� the� joint�

efforts�of�the�entire�staff,�and�al-

so�expressed�high�expectation�on�

the� further� development� of� the�

channels.��

To� celebrate� such� a� mean-

ingful� moment,� all� guests�

opened� champagne� of� success�

and� had� a� toast� for� all� partners.�

Steven,� Haidong� and� channel�

representatives� cut� a� cake� to�

mark� the� successful� opening� of�

the� sales� office� and�wished� PFL�

ever-better�performance.�■

Fosun�Pharma�focuses�on�strategic�development�

to�accelerate�international�cooperation

Recommended